Chardan analyst Geulah Livshits raised the firm’s price target on Lexeo Therapeutics (LXEO) to $25 from $23 and keeps a Buy rating on the shares. The company reported Q3 results and announced it reached alignment with the FDA on registrational endpoints to support accelerated approval of its AAVrh10 GT LX2006 targeting Friedreich’s ataxia cardiomyopathy, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics price target lowered to $19 from $20 at Leerink
- Lexeo Therapeutics Strengthens Leadership with New Board Appointment
- Lexeo Therapeutics reaches FDA alignment on development plan for LX2006
- Lexeo Therapeutics reports Q3 EPS (89c), consensus (68c)
- Lexeo Therapeutics sees cash runway into 2027